{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:05:59Z","timestamp":1785323159960,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"PHRC Interr\u00e9gional 2016 in FRANCE","award":["AOR16076"],"award-info":[{"award-number":["AOR16076"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-09314-7","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:54:04Z","timestamp":1775872444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nintedanib in progressive bronchiolitis obliterans syndrome (BOS) grade 0p-1-2 in lung transplant recipients (INFINITIx-BOS): protocol of a French multicenter randomized controlled trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Olivier","family":"Brugi\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Hirschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Reynaud-Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Demant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Le Pavec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Falque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassima","family":"Si Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Tardivon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Couffignal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the INFINITIx-BOS Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"9314_CR1","doi-asserted-by":"crossref","unstructured":"Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, Brozek J, Glanville AR, Committee IAEBTF, Committee IAEBTF. An international ISHLT\/ATS\/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir. J 2014; 44: 1479\u20131503.","DOI":"10.1183\/09031936.00107514"},{"key":"9314_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.healun.2013.10.022","volume":"33","author":"GM Verleden","year":"2014","unstructured":"Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014;33:127\u201333.","journal-title":"J Heart Lung Transplant"},{"key":"9314_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01416-2020","author":"C Morrone","year":"2021","unstructured":"Morrone C, Smirnova NF, Jeridi A, Kneidinger N, Hollauer C, Schupp JC, et al. Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome. Eur Respir J. 2021. https:\/\/doi.org\/10.1183\/13993003.01416-2020.","journal-title":"Eur Respir J"},{"key":"9314_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.healun.2004.01.009","volume":"24","author":"IP Neuringer","year":"2005","unstructured":"Neuringer IP, Chalermskulrat W, Aris R. Obliterative bronchiolitis or chronic lung allograft rejection: a basic science review. J Heart Lung Transplant. 2005;24:3\u201319.","journal-title":"J Heart Lung Transplant"},{"key":"9314_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1053-2498(02)00398-4","volume":"21","author":"M Estenne","year":"2002","unstructured":"Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21:297\u2013310.","journal-title":"J Heart Lung Transplant"},{"key":"9314_CR6","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1378\/chest.10-2944","volume":"139","author":"R Vos","year":"2011","unstructured":"Vos R, Vanaudenaerde BM, Verleden SE, Van Raemdonck DE, Dupont LJ, Verleden GM. Azithromycin in posttransplant bronchiolitis obliterans syndrome. Chest. 2011;139:1246.","journal-title":"Chest"},{"key":"9314_CR7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1164\/rccm.201002-0211OC","volume":"182","author":"CA Finlen Copeland","year":"2010","unstructured":"Finlen Copeland CA, Snyder LD, Zaas DW, Turbyfill WJ, Davis WA, Palmer SM. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med. 2010;182:784\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"9314_CR8","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.healun.2007.07.027","volume":"26","author":"RR Hachem","year":"2007","unstructured":"Hachem RR, Yusen RD, Chakinala MM, Meyers BF, Lynch JP, Aloush AA, et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant. 2007;26:1012\u20138.","journal-title":"J Heart Lung Transplant"},{"key":"9314_CR9","doi-asserted-by":"crossref","unstructured":"Treede H, Glanville AR, Klepetko W, Aboyoun C, Vettorazzi E, Lama R, Bravo C, Knoop C, Aubert JD, Reichenspurner H, European, Australian Investigators in Lung T. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant. 2012; 31: 797\u2013804.","DOI":"10.1016\/j.healun.2012.03.008"},{"key":"9314_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1055\/s-0033-1348463","volume":"34","author":"SE Verleden","year":"2013","unstructured":"Verleden SE, Vandermeulen E, Ruttens D, Vos R, Vaneylen A, Dupont LJ, et al. Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS). Semin Respir Crit Care Med. 2013;34:352\u201360.","journal-title":"Semin Respir Crit Care Med"},{"key":"9314_CR11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1432-2277.2011.01248.x","volume":"24","author":"GM Verleden","year":"2011","unstructured":"Verleden GM, Verleden SE, Vos R, De Vleeschauwer SI, Dupont LJ, Van Raemdonck DE, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transpl Int. 2011;24:651\u20136.","journal-title":"Transpl Int"},{"issue":"4","key":"9314_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193564","volume":"13","author":"D Ruttens","year":"2018","unstructured":"Ruttens D, Verleden SE, Demeyer H, Van Raemdonck DE, Yserbyt J, Dupont LJ, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a randomized controlled trial. PLoS One. 2018;13(4):e0193564. https:\/\/doi.org\/10.1371\/journal.pone.0193564.","journal-title":"PLoS One"},{"key":"9314_CR13","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1111\/j.1600-6143.2007.02000.x","volume":"7","author":"BD Reams","year":"2007","unstructured":"Reams BD, Musselwhite LW, Zaas DW, Steele MP, Garantziotis S, Eu PC, et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant. 2007;7:2802\u20138.","journal-title":"Am J Transplant"},{"key":"9314_CR14","doi-asserted-by":"publisher","unstructured":"Ensor CR, Rihtarchik LC, Morrell MR, Hayanga JW, Lichvar AB, Pilewski JM, Wisniewski S, Johnson BA, D\u2019Cunha J, Zeevi A, McDyer JF. Rescue alemtuzumab for refractory acute cellular rejection and bronchiolitis obliterans syndrome after lung transplantation. Clin Transplant. 2017;31(4). https:\/\/doi.org\/10.1111\/ctr.12899. Epub 2017 Feb 22.","DOI":"10.1111\/ctr.12899"},{"issue":"Suppl 1","key":"9314_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jdv.12311","volume":"28","author":"R Knobler","year":"2014","unstructured":"Knobler R, Berlin G, Calzavara-Pinton P, Greinix H, Jaksch P, Laroche L, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 1):1\u201337.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9314_CR16","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1097\/TP.0b013e31818bc024","volume":"86","author":"C Benden","year":"2008","unstructured":"Benden C, Speich R, Hofbauer GF, Irani S, Eich-Wanger C, Russi EW, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation. 2008;86:1625\u20137.","journal-title":"Transplantation"},{"key":"9314_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.healun.2009.08.029","volume":"29","author":"MR Morrell","year":"2010","unstructured":"Morrell MR, Despotis GJ, Lublin DM, Patterson GA, Trulock EP, Hachem RR. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2010;29:424\u201331.","journal-title":"J Heart Lung Transplant"},{"key":"9314_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000431382","volume":"90","author":"C Del Fante","year":"2015","unstructured":"Del Fante C, Scudeller L, Oggionni T, Viarengo G, Cemmi F, Morosini M, et al. Long-term off-line extracorporeal photochemotherapy in patients with chronic lung allograft rejection not responsive to conventional treatment: a 10-year single-centre analysis. Respiration. 2015;90:118\u201328.","journal-title":"Respiration"},{"key":"9314_CR19","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.healun.2012.05.002","volume":"31","author":"P Jaksch","year":"2012","unstructured":"Jaksch P, Scheed A, Keplinger M, Ernst MB, Dani T, Just U, et al. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2012;31:950\u20137.","journal-title":"J Heart Lung Transplant"},{"key":"9314_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1600-6143.2004.00709.x","volume":"5","author":"AJ Fisher","year":"2005","unstructured":"Fisher AJ, Rutherford RM, Bozzino J, Parry G, Dark JH, Corris PA. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2005;5:537\u201343.","journal-title":"Am J Transplant"},{"key":"9314_CR21","doi-asserted-by":"crossref","unstructured":"Lebeer M, Kaes J, Lambrech M, Vanstapel A, Beeckmans H, Ambrocio GPL, Vanaudenaerde BM, Verleden SE, Verbeken EK, Neyrinck AP, Ceulemans LJ, Van Raemdonck DE, Verleden GM, Vos R, Leuven Lung Transplant G. Total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation: a single-center experience and review of literature. Transpl Int. 2020;33:216\u2013228.","DOI":"10.1111\/tri.13544"},{"key":"9314_CR22","first-page":"1175","volume":"116","author":"SA Yousem","year":"1992","unstructured":"Yousem SA, Suncan SR, Ohori NP, Sonmez-Alpan E. Architectural remodeling of lung allografts in acute and chronic rejection. Arch Pathol Lab Med. 1992;116:1175\u201380.","journal-title":"Arch Pathol Lab Med"},{"key":"9314_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1378\/chest.86.6.824","volume":"86","author":"CM Burke","year":"1984","unstructured":"Burke CM, Theodore J, Dawkins KD, Yousem SA, Blank N, Billingham ME, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest. 1984;86:824\u20139.","journal-title":"Chest"},{"key":"9314_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1183\/09059180.00004413","volume":"23","author":"M Pain","year":"2014","unstructured":"Pain M, Bermudez O, Lacoste P, Royer PJ, Botturi K, Tissot A, et al. Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype. Eur Respir Rev. 2014;23:118\u201330.","journal-title":"Eur Respir Rev"},{"key":"9314_CR25","first-page":"277","volume":"90","author":"V Brocker","year":"2006","unstructured":"Brocker V, Lehmann U, Langer F, Fellous TG, Mengel M, Brittan M, et al. [Fibroblasts of recipient origin contribute to broncholitis obliterans in human lung transplants]. Verh Dtsch Ges Pathol. 2006;90:277\u201385.","journal-title":"Verh Dtsch Ges Pathol"},{"key":"9314_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1600-6143.2009.02953.x","volume":"10","author":"LA Borthwick","year":"2010","unstructured":"Borthwick LA, McIlroy EI, Gorowiec MR, Brodlie M, Johnson GE, Ward C, et al. Inflammation and epithelial to mesenchymal transition in lung transplant recipients: role in dysregulated epithelial wound repair. Am J Transplant. 2010;10:498\u2013509.","journal-title":"Am J Transplant"},{"key":"9314_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1600-6143.2009.02558.x","volume":"9","author":"S Hodge","year":"2009","unstructured":"Hodge S, Holmes M, Banerjee B, Musk M, Kicic A, Waterer G, et al. Posttransplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. Am J Transplant. 2009;9:727\u201333.","journal-title":"Am J Transplant"},{"key":"9314_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1164\/rccm.2102106","volume":"166","author":"RM Aris","year":"2002","unstructured":"Aris RM, Walsh S, Chalermskulrat W, Hathwar V, Neuringer IP. Growth factor upregulation during obliterative bronchiolitis in the mouse model. Am J Respir Crit Care Med. 2002;166:417\u201322.","journal-title":"Am J Respir Crit Care Med"},{"key":"9314_CR29","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1111\/j.1600-6143.2005.00999.x","volume":"5","author":"T Maruyama","year":"2005","unstructured":"Maruyama T, Jaramillo A, Narayanan K, Higuchi T, Mohanakumar T. Induction of obliterative airway disease by anti-HLA class I antibodies. Am J Transplant. 2005;5:2126\u201334.","journal-title":"Am J Transplant"},{"key":"9314_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0198-8859(03)00038-7","volume":"64","author":"A Jaramillo","year":"2003","unstructured":"Jaramillo A, Smith CR, Maruyama T, Zhang L, Patterson GA, Mohanakumar T. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol. 2003;64:521\u20139.","journal-title":"Hum Immunol"},{"key":"9314_CR31","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1164\/rccm.200601-044OC","volume":"174","author":"JM Tikkanen","year":"2006","unstructured":"Tikkanen JM, Hollmen M, Nykanen AI, Wood J, Koskinen PK, Lemstrom KB. Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. Am J Respir Crit Care Med. 2006;174:1145\u201352.","journal-title":"Am J Respir Crit Care Med"},{"key":"9314_CR32","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1164\/ajrccm.160.4.9802006","volume":"160","author":"EA Kallio","year":"1999","unstructured":"Kallio EA, Koskinen PK, Aavik E, Buchdunger E, Lemstrom KB. Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat. Am J Respir Crit Care Med. 1999;160:1324\u201332.","journal-title":"Am J Respir Crit Care Med"},{"key":"9314_CR33","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.ajpath.2012.07.021","volume":"181","author":"R Krebs","year":"2012","unstructured":"Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Yla-Herttuala S, et al. Critical role of VEGF-C\/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis. Am J Pathol. 2012;181:1607\u201320.","journal-title":"Am J Pathol"},{"key":"9314_CR34","doi-asserted-by":"publisher","first-page":"10385","DOI":"10.1073\/pnas.89.21.10385","volume":"89","author":"MI Hertz","year":"1992","unstructured":"Hertz MI, Henke CA, Nakhleh RE, Harmon KR, Marinelli WA, Fox JM, et al. Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci U S A. 1992;89:10385\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9314_CR35","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1164\/ajrccm.161.6.9905049","volume":"161","author":"JM Charpin","year":"2000","unstructured":"Charpin JM, Stern M, Grenet D, Israel-Biet D. Insulinlike growth factor-1 in lung transplants with obliterative bronchiolitis. Am J Respir Crit Care Med. 2000;161:1991\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"9314_CR36","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1053-2498(99)00047-9","volume":"18","author":"A El-Gamel","year":"1999","unstructured":"El-Gamel A, Sim E, Hasleton P, Hutchinson J, Yonan N, Egan J, et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant. 1999;18:828\u201337.","journal-title":"J Heart Lung Transplant"},{"key":"9314_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/01902148.2017.1354408","volume":"43","author":"M von Suesskind-Schwendi","year":"2017","unstructured":"von Suesskind-Schwendi M, Boxhammer E, Hirt SW, Schreml S, Schmid C, Wollin L, et al. The activity of nintedanib in an animal model of allogenic left lung transplantation resembling aspects of allograft rejection. Exp Lung Res. 2017;43:259\u201370.","journal-title":"Exp Lung Res"},{"key":"9314_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/01902148.2020.1738594","volume":"46","author":"E Boxhammer","year":"2020","unstructured":"Boxhammer E, Lehle K, Schmid C, von Suesskind-Schwendi M. Anti-oxidative effect of the tyrosine kinase inhibitor nintedanib: a potential therapy for chronic lung allograft dysfunction? Exp Lung Res. 2020;46:128\u201345.","journal-title":"Exp Lung Res"},{"key":"9314_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1124\/jpet.113.208223","volume":"349","author":"L Wollin","year":"2014","unstructured":"Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349:209\u201320.","journal-title":"J Pharmacol Exp Ther"},{"key":"9314_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209786","volume":"13","author":"M Kishi","year":"2018","unstructured":"Kishi M, Aono Y, Sato S, Koyama K, Azuma M, Abe S, et al. Blockade of platelet-derived growth factor receptor-beta, not receptor-alpha ameliorates bleomycin-induced pulmonary fibrosis in mice. PLoS One. 2018;13:e0209786.","journal-title":"PLoS One"},{"key":"9314_CR41","first-page":"1481","volume":"24","author":"ZW Liu","year":"2020","unstructured":"Liu ZW, Zhao MY, Su XL, Ye TH, Zhuang YJ, Zhang Y, et al. The antifibrotic effect and mechanism of a novel tyrosine kinase inhibitor, ZSP1603, in preclinical models of pulmonary fibrosis. Eur Rev Med Pharmacol Sci. 2020;24:1481\u201391.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"Suppl 119","key":"9314_CR42","first-page":"115","volume":"37","author":"I Atanelishvili","year":"2019","unstructured":"Atanelishvili I, Akter T, Noguchi A, Vuyiv O, Wollin L, Silver RM, et al. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease. Clin Exp Rheumatol. 2019;37(Suppl 119):115\u201324.","journal-title":"Clin Exp Rheumatol"},{"key":"9314_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12931-017-0654-2","volume":"18","author":"S Sato","year":"2017","unstructured":"Sato S, Shinohara S, Hayashi S, Morizumi S, Abe S, Okazaki H, et al. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res. 2017;18:172.","journal-title":"Respir Res"},{"key":"9314_CR44","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"9314_CR45","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.rmed.2014.04.011","volume":"108","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, et al. Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108:1023\u201330.","journal-title":"Respir Med"},{"key":"9314_CR46","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/thoraxjnl-2016-209701","volume":"73","author":"L Richeldi","year":"2018","unstructured":"Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018;73:581\u20133.","journal-title":"Thorax"},{"key":"9314_CR47","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137.","journal-title":"Ann Intern Med"},{"key":"9314_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319\u201338.","journal-title":"Eur Respir J"},{"key":"9314_CR49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"Laboratories ATSCoPSfCPF","year":"2002","unstructured":"Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"9314_CR50","first-page":"43","volume":"13","author":"C Bouchet","year":"1996","unstructured":"Bouchet C, Guillemin F, Hoang Thi TH, Cornette A, Briancon S. [Validation of the St George\u2019s questionnaire for measuring the quality of life in patients with chronic obstructive pulmonary disease]. Rev Mal Respir. 1996;13:43\u20136.","journal-title":"Rev Mal Respir"},{"key":"9314_CR51","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079\u201387.","journal-title":"N Engl J Med"},{"key":"9314_CR52","doi-asserted-by":"publisher","first-page":"117954842110060","DOI":"10.1177\/11795484211006050","volume":"15","author":"F Rahaghi","year":"2021","unstructured":"Rahaghi F, Belperio JA, Fitzgerald J, Gulati M, Hallowell R, Highland KB, et al. Delphi consensus recommendations on management of dosing, adverse events, and comorbidities in the treatment of idiopathic pulmonary fibrosis with nintedanib. Clin Med Insights Circ Respir Pulm Med. 2021;15:11795484211006050.","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"9314_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081123","author":"S Hopewell","year":"2025","unstructured":"Hopewell S, Chan AW, Collins GS, Hrobjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. Lancet. 2025. https:\/\/doi.org\/10.1136\/bmj-2024-081123.","journal-title":"Lancet"},{"key":"9314_CR54","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.healun.2019.03.009","volume":"38","author":"GM Verleden","year":"2019","unstructured":"Verleden GM, Glanville AR, Lease ED, Fisher AJ, Calabrese F, Corris PA, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-a consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019;38:493\u2013503.","journal-title":"J Heart Lung Transplant"},{"key":"9314_CR55","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1164\/rccm.200212-1424BC","volume":"168","author":"SG Gerhardt","year":"2003","unstructured":"Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003;168:121\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"9314_CR56","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1097\/01.TP.0000122412.80864.43","volume":"77","author":"GM Verleden","year":"2004","unstructured":"Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004;77:1465\u20137.","journal-title":"Transplantation"},{"key":"9314_CR57","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.healun.2024.05.013","volume":"43","author":"MP Combs","year":"2024","unstructured":"Combs MP, Belloli EA, Gargurevich N, Flaherty KR, Murray S, Galban CJ, et al. Results from randomized trial of pirfenidone in patients with chronic rejection (STOP-CLAD study). J Heart Lung Transplant. 2024;43:1468\u201377.","journal-title":"J Heart Lung Transplant"},{"key":"9314_CR58","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.bbmt.2014.06.014","volume":"20","author":"CJ Galban","year":"2014","unstructured":"Galban CJ, Boes JL, Bule M, Kitko CL, Couriel DR, Johnson TD, et al. Parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1592\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"9314_CR59","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","volume":"58","author":"S Wind","year":"2019","unstructured":"Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, et al. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet. 2019;58:1131\u201347.","journal-title":"Clin Pharmacokinet"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09314-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09314-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09314-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:02:35Z","timestamp":1776067355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-025-09314-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9314"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09314-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"298"}}